Roth Capital raised the firm’s price target on Sanuwave Health (SNWV) to $54 from $49 and keeps a Buy rating on the shares after the company reported “strong” Q2 results and reiterated its FY25 revenue forecast of $48M-$50M. The firm’s new $15.2M FY25 AEBITDA estimate is up from $14.2M previously, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNWV: